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ABSTRACT 
 
 
Photodynamic Therapy (PDT) has found use in a wide-array of clinical applications such as in 
cancer and acne treatment. Photodynamic therapy, uses a photosensitive compound activated by a 
specific wavelength photon to produce cytotoxic oxygen species (either in free radical form or in 
singlet form). However, weak penetration of visible, infrared, and UV light into the body to 
activate the photosensitive compound significantly limits the use of PDT in cancer treatment. 
Additionally, PDT current lacks an effective dosimetry technique or means of quantifying the 
number of activated photosensitizers for investigative studies has proven difficult as well. Many 
researchers have delved into investigating x-ray induced PDT, which in combination of x-ray 
fluorescence computed tomography (XFCT), can produce a quantifiable therapeutic effect at 
greater bodily depths. This work demonstrates a novel combinatorial system of X-ray Fluorescence 
and X-ray Luminescence Computed Tomography (XLCT) to image LaF3 and Y2O3 nanoparticles. 
A 3D XFCT/CT image of a mouse phantom conjugated with a NMR tube containing bromide and 
Y2O3 was produced. Additionally, a cross sectional imaging in XFCT/XLCT/CT of a mouse 
phantom with microcapillaries filled with LaF3:Tb3+ and Y2O3:Eu3+ attached. The results 
demonstrated the plausibility of using a XFCT/XLCT/CT setup for monitoring therapeutic 
nanoparticles, but acquisition time and penetration depth issues will need to be addressed first.  
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CHAPTER 1: INTRODUCTION 
1.1 Objective 
With the emergence of the anti-tumor breast cancer drug, abraxane, many research 
groups have begun investigating nanoparticles as a therapeutic agent for cancer treatment [1]–
[3]. Nanoparticles conjugated with targeting ligands can accumulate at specific tumor sites to 
enhance therapeutic effects while minimizing damage to healthy cells [4], [5]. One specific type 
of nanoparticle-mediated cancer treatment gaining traction and clamor is photodynamic therapy 
(PDT), in which nanoparticles produce cytotoxic singlet oxygen upon irradiation of light [2]. 
However, traditional photodynamic therapy typically uses visible, near infrared, infrared, 
or ultraviolet light to induce singlet oxygen production in nanoparticles [2], [6]. However, this 
incident light lacks significant penetration depth limiting photodynamic therapy to a few 
millimeters to centimeters below skin. X-ray-activated photodynamic therapy techniques have 
gained much attention in the hopes of imparting therapeutic effects at greater depths than is 
possible with traditional photodynamic therapy [6], [7].  Interestingly, the very process that 
underlies X-ray induced therapeutic effects could also generate X-ray fluorescence (with metal-
based nanoparticles) and/or X-ray luminescence (XL), which could be used to monitor the 
delivery and distribution of PDT agents and the subsequent therapeutic activation process. This 
leads to the possibility of using (XFCT) and X-ray luminescence computed tomography (XLCT) 
for monitoring therapeutic delivery during radiation therapy, which this work explores.   
For instance, during the microbeam therapeutic delivery process, a highly collimated X-
ray beam irradiates the object. The pre-administrated metal-containing nanoparticles (NPs) 
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preferably absorb the X-rays to produce therapeutic effects, either indirectly through mechanisms 
such as photosensitization [1, 2] and  thermal ablation [8], or directly from radiation effects 
induced by low-energy secondary electrons (including Auger electrons) [9]. Resultant XF signals 
could determine the distribution of the NPs in the object and the absorption of X-ray energy 
through photoelectron interactions. The XL signals could provide quantitative information and 
indirect spatial mapping of the scintillation process induced by the X-ray irradiation of 
nanophosphors conjugated with photosensitizers. Finally, the micro-CT images provide 
structural details of the object for confirmation of the delivery of the beam to the target area. 
Combining these three imaging techniques would provide a unique tool for guiding therapeutic 
delivery with highly detailed spatial and functional information. This work examines the 
feasibility of such a combinatorial system.     
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CHAPTER 2: BACKGROUND OF PHOTODYNAMIC THERAPY 
2.1 Basic Principles of Photodynamic Therapy and Photochemistry 
 
Photodynamic therapy predominantly uses light as its means of operation for cancer 
treatment. A light-sensitive chemical agent known as a photosensitizer produces cytotoxic effect. 
Through unknown or various means (depending on the type of photosensitizer), the 
photosensitizer accumulates in the tumor location. Upon light irradiation, singlet oxygen is 
produced. 
Singlet oxygen is a very excited and reactive molecule capable of interacting with biological 
relevant molecules found in membranes such as unsaturated lipids, cholesterol, tryptophan, 
histidine, and methionine [10].  Additionally, the singlet oxygen has a short lifetime, within 40 
nanosecond, and a radius of action less than 20 nanometers [10]. This allows for a very specific 
targeting and localization with a tumor site. 
Singlet oxygen is produced when light excites the photosensitizer, elevating it to and excited 
electron energy state. In this excited, several different mechanisms can occur. The sensitizer can 
return to ground state by emitting light in a process called fluorescence. The sensitizer can react 
directly with other molecules in tissue to produce radical intermediates. However, to produce the 
actual photodynamic effect, the energetic sensitizer would enter a triplet state through 
“intersystem crossing”, in which the excited electron will go through a spin conversion to a 
lower excited state [10]. For an effective photosensitizer, this triplet state must have a long 
lifetime. In this triplet state, the sensitizer reacts with oxygen leading to singlet oxygen 
production as seen in Figure 2.1 [10].  
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Figure 2.1 A diagram representation of singlet oxygen production via the photosensitizer [10].  
 
 
2.2 Cytotoxic Effects of Photodynamic Therapy 
 
   
Singlet oxygen can cause damage of membranes which causes swelling, bleb formation, and 
the halting of membrane enzymes. The membrane damage can cause the release of necessary 
proteins such as cytochrome c, which ultimately led to ATP depletion. Interestingly, PDT has 
varying potential for causing DNA damage as some sensitizing agents have a low probability of 
accumulating in cell nuclei while others can cause breakage in the double strands of DNA.  
 
 
 
 
 
 
 5 
 
CHAPTER 3: BACKGROUND OF X-RAY FLUORESCENCE 
 
3.1 A Brief Overview of Medical Based X-Ray Fluorescence 
Much of the medical exploration of x-ray fluorescence based imaging comes from the 
mapping of key naturally occurring trace metals in biological samples. Being able to map these 
metals and their relevant processes in vivo can easily have numerous applications in clinical 
medicine. Such mapping can identify indicative pathologies of metals such as copper or 
magnesium in Parkinson’s disease and other neurodegenerative disorders [11]. More specifically, 
recent research found a lack of copper within the substantia nigra and locus coeruleus of the 
brain in Parkinson’s disease patients [12]. However, many of these studies and investigations are 
conducted using synchrotron radiation, and cannot be practiced in vivo due to dosage concerns. 
To overcome this limitation, nanoparticles targeted to specific biological targets to enhance 
their output signal and reduce the need for a synchrotron source. For instance, recent work shows 
clinical ability of mapping naturally occurring trace metals includes the use of fluorescence 
nanoparticles coupled to ligands to serve as biomarkers on DNA [13]. With the growing study of 
the role of traces metals in genomics and proteomics, spatial resolute maps of the concentration 
of these trace metals have become critical [14]. Currently, X-ray fluorescence computed 
tomography (XFCT) has generated much attention as a potential means for mapping these trace 
metals since it does not require destructive sample preparation like those of SEM EDX, PIXE, 
and other methods. X-ray fluorescence analysis (XRF) has shown to be a viable method to 
acquire these concentrations of metals and markers of interest, but without providing spatial 
information.  The amount of information acquired from X-ray fluorescence can be increased 
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significantly through the means of producing an image as done in X-ray Fluorescence Computed 
Tomography (XFCT), which can provide both spectral and spatial data. 
 
3.2 X-ray Fluorescence Analysis and X-ray Fluorescence Computed Tomography 
X-ray fluorescence analysis fundamentally depends on the ability for elements to produce 
signature X-rays when they interact with an initial primary X-ray. X-rays, in general, are 
produced from the atomic electron transitions and, therefore, contain characteristics specified by 
their element of origin. The typical stable atomic structure contains electron orbitals with 
correspond to specific distinct energy levels [15].  To remove an electron from its orbit, a certain 
level of energy, or binding energy, must be spent. If the removal of an inner orbital electron 
occurs, an outer electron may jump in to the new vacancy. This electron transition may produce a 
characteristic X-ray of energy equal to the difference of the two orbital binding energies. X-ray 
fluorescence occurs when a primary X-ray provides the initial energy required to remove an 
inner orbit electron, with the resulting electron transition producing the “secondary” fluorescent 
X-ray. 
XRF utilizes the principle concept that the measured X-ray fluorescence intensity of a peak 
of an element relates to the concentration of the element in a sample [16]. This relation can be 
identified through a calibration procedure, which measures peak values of a known concentration 
of the element to be determined [17].  The XFCT modality produces images as well and typically 
incorporates a monochromatic X-ray beam to probe a rotating or translating sample. The incident 
X-rays induce characteristic fluorescence X-rays, which are used to construct a 3-D element 
distribution of the sample. Initial implementations of the system required the use of a high 
intensity synchrotron source to provide the monoenergetic X-rays. They also incorporate known 
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reconstructive techniques such as filtered-back projection or iterative reconstruction [18]. 
However, more recent studies have successfully used bench-top sources to quantify 
concentrations of lead in bone and gold nanoparticles in small tubes, albeit with relatively high 
concentrations [19], [20].  
3.3 The Competing Modalities and their Limitations 
Magnetic Resonance Spectroscopy (MRS) competes with X-ray fluorescence-based 
spectral analysis in their ability to quantize certain types of trace metals, such as gadolinium and 
iron, in a sample. MRS uses high strength magnetic fields in conjunction with a RF pulse at a 
specified frequency to examine particular in a region of interest [11], [12]. Although magnetic 
resonance based spectroscopy has pervasive use for in vivo use, they suffer from intrinsically low 
sensitivity with SNR value of 3:1 being commonly used [21]. This significantly low SNR is 
magnitudes less in order than fluorescence-based imaging and mass spectrometry [21].  
Mass spectroscopy also has the capability to identify the chemical composition of trace 
elements in a sample. Mass spectrometry measures the mass-charge ratio to determine the 
presence of certain nuclei. However, mass spectrometry requires the use of vacuums and sample 
preparation, which often results in sample destruction. This makes mass spectrometry not 
applicable for in vivo application [14], [22], [23] 
3.4 Limitations of X-ray Fluorescence Analysis and X-ray Fluorescence Computed 
Tomography 
 
While these and other studies suggest that current XFCT/XRF systems can capably 
perform in vivo studies, they are also subject to a series of questions, such as the amount of 
contrast agents (e.g. metal nanoparticles) or the excessive dose needed to obtain acceptable 
images [3,4]. A Monte Carlo simulation study suggested that less than .5% by weight GNP 
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sample with 1 mGy dosage would provide poor image contrast with a current XFCT system 
[24][19]. These are mainly due to the intrinsically low interaction probability of the incident X-
rays with the relatively low concentration of the metal content. Additionally, such studies show a 
limited sensitivity of 1µg/g [25]. 
3.5 Addressing the Limitations 
 
With such limitations, can one map naturally occurring metals such as copper in mouse 
brain under in vivo settings be feasible, and can one do this with a benchtop X-ray source instead 
of a synchrotron X-ray source? In this work, we explore an alternative approach that relies on 
mechanical collimation and X-ray detectors to construct certain imaging geometries capable of 
mapping the elemental distribution of these trace metals without the need for full 3-D image 
reconstruction using benchtop X-ray sources. Earlier works by this group have demonstrated the 
plausibility of such imaging techniques without the use of computational image reconstruction 
techniques using synchrotron radiation from the Advance Photon Source [26]. By designing the 
aperture with a large open fraction (say 10% or more), one just needs to count how many 
fluorescence X-rays pass through the aperture, which will directly provide the elemental 
concentration values. Therefore, the metal concentration derived in this way is free of the so-
called decoding penalty associated with 3-D imaging reconstruction, and could potentially have 
reduced statistical noise. By using high sensitivity imaging detectors and apertures with large 
open fractions, this approach would have the potential of offering the optimum sensitivity for 
quantifying the metal concentrations in 3-D samples.  
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CHAPTER 4: BACKGROUND OF X-RAY LUMINESCENCE 
 
4.1 Potential Medical Applications for X-ray Luminescence 
Quite similar to X-ray fluorescence, the rise of X-ray luminescence came from the need to 
combine the anatomical information of CT with information of the molecular processes that 
underlie various diseases. However, unlike X-ray fluorescence, X-ray luminescence requires the 
use of nanophosphors, scintillators, or the like to produce the visible light being imaged. 
However, XLCT has a poorer spatial resolutions at greater depths due to higher levels of 
scattering at greater depths [27]. This can be compensated for through information provided by 
XFCT, which maintains a good spatial resolution at greater depths 
 
4.2 An Overview of X-ray Luminescence and X-ray Luminescence Computed Tomography 
X-ray luminescence depends upon the process known as scintillation, in which X-rays are 
converted into visible light. These x-rays deposit energy into a target material causing the release 
of secondary electrons. The released high energy electrons cause further ionization downstream 
which ultimately results in the production of a large amount of low energy electrons. If the target 
is not scintillator, the energy of these electrons emits into heat. In scintillators, the electrons 
excite ion dopants into a temporarily stable excited electronic state. When this excited state 
returns back to ground, optical photons are released [28]. 
The emitted light typically falls within certain ranges of wavelengths; thus, certain 
nanophosphors or scintillators may emit green light while others could emit red. This allows for 
the targeting and separation of multiple nanophosphors injected into the body. 
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Combining this process with typical tomographic methods creates what is known as XLCT.  
In XLCT, a sample is irradiated by a pencil-collimated x-ray beams as it translates or rotates at 
set intervals in a geometry similar to that of first generation X-ray CT [28]. This is setup is 
shown in Figure 4.1. The nanophosphors are excited within a given irradiated volume emit 
visible light photons that are detected by an optical camera. The measured flux of these photons 
is proportional to the amount of nanoparticles in the irradiated volume. Various rotations and 
translations of both the motor and sample can ultimately produce a sinogram similar to that of 
conventional CT. Typical CT reconstruction techniques can then be applied to produce an image 
of nanophosphorous volume. 
 
 
 
 
 
 
 
Figure 4.1—A first generation XLCT setup with a geometry similar to that of first generation X-ray CT  
[35]. 
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4.3 The Competing Modalities and Their Limitations 
XLCT is in the realm of molecular imaging. The most clinically available molecular 
imaging tools would be Positron Emission Tomography (PET) and Single Photon Emission 
Computed Tomography (SPECT). Both these modalities require the use of radiopharmaceuticals 
that emit high energy gamma rays. These radiotracers accumulate in the specific regions of the 
body to monitor various biological processes such as glucose uptake. The high energy gamma 
rays can penetrate tens of centimeters of tissue, which is useful for whole body imaging [29]. 
These modalities also have high sensitivity and specificity, but have poor spatial resolution in the 
realm of millimeters when compared to other modalities. 
Another optical imaging modality known as optical fluorescence imaging is the 
mainstream method for preclinical imaging. Fluorescence imaging utilizes optically fluorescent 
dyes that are taken up by cells. However, XLCT in comparison to this modality has greater 
spatial resolution at imaging depths. Optical fluorescence imaging is limited by the scattering of 
emitted optical light at these greater depths [28].  
4.4 Limitations of X-ray Luminescence Computed Tomography 
 
Many of the limitations of XLCT are akin to those of XFCT. Most current methodologies 
of image acquisition can be considered quite long for X-ray exposure. Additionally, since XLCT 
relies on probabilities of x-ray interaction with the nanophosphors and the probability of light 
emission. Only large concentrations (.2 mg/mL to 1 mg/mL) of nanoparticles/nanophosphors 
have been used in demonstrations of XLCT [27]. While some studies suggest that current XLCT 
systems can capably perform in vivo studies, such doses of nanoparticles could be deemed 
impractical for such studies [30]. Compare to XFCT, however, XLCT produces many more 
emission photons. At most, only one x-ray fluorescent photon can be produced by an incident x-
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ray photon while several optical photons can be emitted in XLCT. However, XFCT emits higher 
energy x-ray which can penetrate at greater depths that optical photons. Thus, in comparison 
XLCT is still limited by depth as well. 
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CHAPTER 5: IMAGE FORMATION  
 
5.1. Physically Defining a ROI using Apertures for XLCT and XFCT 
 
If one could define the boundary of a ROI inside a sample with images from X-ray CT or other 
imaging techniques, then a specifically designed aperture would allow only fluorescence or 
optical X-rays from a linear segment of the ROI to register in our position sensitive X-ray 
detector. The system then scans the object across the beam. At any given beam position, a 
specific aperture will be placed in front of the detector to allow only those fluorescence X-rays 
from the ROI volume being irradiated in the sample. Given the known geometry, one can obtain 
a line integral of fluorescence X-rays through the ROI. By moving the object across the beam, 
one can derive a total concentration of the target metal within the ROI without running into the 
problem of 3-D image reconstruction from projections. Fig. 2.1a depicts this approach of 
imaging. The system incorporates an ultrahigh resolution spectrometer (the ANDOR camera in 
Figure 1a) coupled with the specially crafted set of apertures (shown in Figure 2.1c) placed 
perpendicular to the X-Ray CT detector (Paxscan 1313).  While both of these Figures are 
specified for X-ray Fluorescence Computed Tomography, the same geometry is used for XLCT 
with the only difference being the exchange of the CCD with an EMCCD. 
5.2. Image Formation 
 
The volume-selective counting technique allows for acquiring spectral information, but also 
for image formation through mapping techniques. With the geometry of the system already 
predetermined, the pencil beam would interrogate the sample along a precisely known line. By 
translating the sample perpendicular to the beam in steps equivalent to the beam width, thus 
limiting the pixel width of the image to the beam width in one dimension, the system examines 
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an entire slice. By additionally translating in the vertical direction, the whole sample is 
interrogated, and a 3-D image can be obtained. Using the tapering of the aperture, the originating 
position of the fluorescence X-rays or luminescent phtons can be determined along the pencil 
beam’s path. Thus, as seen in Fig 5.2 below, the final line segment is constructed by summing 
down the columns of the spectrometer. By simply placing these line segments next to each other, 
our final image is pieced together. 
5.3. Spectral and Image Correction via X-Ray CT 
 
The X-ray CT detector incorporated into the system does not only define the ROI within a 
sample, but also provide the X-ray attenuation information. Attenuation affects the gathered 
data in two ways: first by attenuating the incoming pencil beam, and secondly by attenuating the 
outgoing fluorescence X-rays. Without correcting for these sources of attenuation, an otherwise 
uniform sample would appear with a radial gradient with its minimum intensity at the point 
furthest away from both the pencil beam source and detector. The density information obtained 
through the X-ray CT system would correlate to relevant attenuation information that will help 
correct these attenuation effects. Many works have been published on the topic of attenuation 
correction, but a simple version of the correction is shown below [31], [32].  
𝐼𝐼(𝑥𝑥, 𝑦𝑦) = 𝐼𝐼0 ∗ 𝑝𝑝 ∗ �� 𝜇𝜇𝑎𝑎(𝑢𝑢,𝑦𝑦)𝑑𝑑𝑥𝑥
0
𝑢𝑢� ∗ �� � � 𝜇𝜇𝑓𝑓(𝛼𝛼, 𝛾𝛾, 𝑟𝑟)𝑑𝑑𝑟𝑟2(𝛼𝛼,𝛾𝛾)
0
𝑟𝑟
𝛼𝛼2
𝛼𝛼1
𝛾𝛾2
𝛾𝛾
� 
Equation 5.1 I(x,y) is the measured intensity at pixel (x,y). I0 is the initial incident beam 
intensity. p is the fluorescent coefficient, which functions as the probability of fluorescence 
occurring for a given mass of an element in a given volume. μa is the attenuation coefficient 
at incident beam energy at the given pixel position. Since the geometry is setup in such a 
way that the x-axis is parallel to the incident beam, u works as a dummy variable to note 
the distance the beam has traveled from 0 to pixel x. For the triple integral, the system is 
defined in spherical coordinates with α as the azimuthal angle, γ being the zenith, and the 
origin at (x,y). The angle integral limits are defined through the observed solid angle 
between the spherical origin and the detector space. The r limits are the boundaries of the 
sample. μf  is the attenuation that occurs at the fluorescence energy at the given pixel 
position v.  
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Figure 5.1: (A) The imaging system includes an X-ray CT system in conjunction with a CCD or 
EMCCD  coupled with specially designed apertures. (B) The system translates the sample and 
various apertures can be used to achieve a highly sensitive photon count for a various specified 
segment of a ROI. (C) Every slit of the 64-slitted aperture shown is designed to examine the 
same 1 cm segment to provide a higher sensitivity count. (D) All the different apertures are to be 
produced on a single piece so that changing slits while scanning the sample becomes a matter of 
translating the aperture piece along the y-axis. 
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Figure 5.2: (A) When imaging, a linear segment of the ROI can be obtained by 
summing down the columns of the pixels of the projection as seen above. (B) Translating 
the sample via motors and then interrogating the new section and summing down the 
detectors column would produce a new line segment. When pieced together, these 
segments compose a 2D image or “slice” of the sample (C). 
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CHAPTER 6: MATERIALS AND METHODS 
6.1. Overview of Experimental Design 
 
Typical XFCT and XLCT image construction scans across a specimen as the specimen 
takes rotational steps. Sinograms are produced from this model of specimen interrogation 
through the use of non-position sensitive detectors. The sinograms are then used to reconstruct 
an image. The volume selective counting technique used in this work uses a direct mapping of 
sample via translation to acquire the image. The laboratory already contained much of the 
experimental setup needed to demonstrate the feasibility of a combined XLCT/XFCT setup. 
Our previous works in XFCT along with the aperture design dictated much of our geometrical 
layout [8]. Two different sets of studies and experiments were performed on two different but 
very similar setups. The first study simply demonstrated a combined XFCT/CT image of a 
nanoparticle filled tube attached to a 3D printed mouse phantom. The second study performed 
a combination of XFCT/XLCT/CT of a 3D printed mouse with two nanoparticle-filled 
microcapillary tubes attached. 
6.2. Overview of Experimental Setup for Combined XFCT/CT  
The system comprises of two X-ray sources, two detectors, four linear stage motors, 
and a rotational motor. The sample translates between two planes, upper and lower, with the 
upper plane containing X-ray CT equipment and the lower consisting of our XFCT design as 
seen in Fig. 3.  
The X-ray CT plane consists of an Oxford Instruments polychromatic source—capable 
of emitting up to 50 keV photons—set across either a Varian Paxscan 1313 detector or a Andor 
Zyla 5.5. The flat panel detector encompasses 1024x1024 pixels of 127 μm x 127 μm in size 
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and covering a total area of 169 cm2. The spectrometer is a CCD camera (Andor DO936N) 
containing a sensor area of 2048 × 2048 square pixels of 13.5 µm × 13.5 µm in size. 
The lower plane consists of a monochromatic benchtop X-ray beam from XOS placed 
adjacent to a spectrometer coupled with a set of interchangeable multi-slit apertures. The system 
uses the set of motors to transfer the sample between planes as well as to properly scan our ROI. 
The four motors are capable of translation movement on the nanometer scale as well as precise 
rotation —a feature necessary as resolution of the mapping depends on the precision of the setup 
geometry. Figure 4 shows this setup.  
Currently, the manufacturer specifies that the monochromatic X-ray source can focus 
unto a spot of 0.1 – 0.3 millimeter in diameter with an intensity of roughly send 17 keV at 
approximately 3x109 Mo K X-rays per second passing through the cross section per second. 
Thus, this beam thickness will define up to two of the dimensions of our voxel while each 
aperture can specify the remaining dimensions. 
Figure 6.1: (A) The Geometry of the XFCT setup. The slit aperture is attached to the CCD and 
the sample is roughly 1 centimeter away from the slit. (B) The mouse phantom with the double 
tube attached. 
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6.3. Experimental Procedure for Combined XFCT/CT 
 
For initial proof of concept, a double tube phantom was constructed containing Y2O3 
nanoparticles in the outer tube and NaBr in the inner tube. The outer diameter of larger tube was 
5 mm while the outer diameter of the smaller tube was 3 mm. The thickness of both the tube 
walls was 500 microns.  The concentration of the Y2O3 was 118 mg/ml and the concentration of 
the NaBr was 172.6 mg/mL. This double tube was then attached to a mouse phantom, which 
serves as the sample. 
The experiments used a single 100 micrometer slit aperture placed in front of the Andor 
CCD. Since the XOS source functions more akin to an incredibly narrow cone beam, the beam 
width at the sample’s position must be determined. The Paxscan 1313 detector, placed at the 
sample position, resolved the beam width to be 100 micrometers. 
Once the sample was setup, the sample was raised into the upper place in order to take an 
X-ray CT image. A X-ray CT image of the mouse was acquired in order to better define 
boundaries of the ROI, obtain an attenuation map, as well as to obtain a magnified view of the 
fish sample. For the image, a 50 keV voltage was applied to the tube as was as a 1.mA current.  
After acquisition of the CT image, the motors lowered the sample to the fluorescence 
system. The pencil beam (XOS source) was set to send 17 keV at approximately 1.55x107 Mo K 
X-rays per second at the focal point of the beam. The Andor CCD was placed with a slit in front 
of the camera and set to acquire 1000 frames with a 10 second exposure per cross-sectional 
position. Accounting for readout time, this translates to about 3 hours per position with 50 
positions being acquired. After 1000 frames were obtained, the motors translated the sample 100 
micrometers in the direction away from the detector and towards the motor (as seen in Fig. 3). 
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After reaching the end of the defined boundaries, an image was directly mapped using earlier 
described methods. 
6.4. Experimental Procedure for Combined XFCT/XLCT/CT Setup 
The combined setup has a similar setup to the previous setup although with a few 
additional changes. The XOS source was replaced with the Xenocs source, which also has a 17.4 
keV monochromatic source. It however also has a larger output of 3x109 photons/s in the 100 
micron diameter focal spot. Additionally, another transmission camera was added to the setup. 
The Andor Zyla CMOS camera contains 2560 by 2180 square pixels of 6.5 μm pitch.  
Additionally, a Andor iXon electron multiplying charge-coupled device (EMCCD) was 
also used to acquire photons for XLCT. The Andor iXon contains 512 by 512 pixels of 16 μm 
square size. This sample was placed directly across from the CCD as seen in Figure 6.2A. 
The sample also is a mouse phantom, but instead contains two micro capillary tubes filled 
with Y2O3:Eu+3 and the other filled with LaF3:Tb+3. These nanoparticles could not be dissolved 
and thus were filled into the microcapillary tubes as powders. These microcapillaries had an 
outer diameter of .0355 inches and an inner diameter of .0248”. 
Monochromatic Source 
X-Ray CT Source 
CCD Camera 
Sample Holder 
B 
B 
A 
Figure 6.2: (A) The combined modality setup. The EMCCD (top-center) is set across the CCD 
in the image. (B) The mouse sample containing Y2O3 nanoparticles and LaF3 nanoparticles 
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Aside from the inner and outer diameter differences the image acquisition method for the 
X-ray CT and XFCT was the same as the previous experiment. The microcapillaries on the 
mouse phantom were oriented in such a way that the incident beam would hit the nanoparticles 
without attenuation from the mouse and the emission photons would reach the CCD. However, 
only 15 positions were necessary to image the microcapillary tubes since their diameters were 
significantly smaller. 720 frames of 10 second exposure times were acquired for each position 
using the slit collimated CCD. 
After XFCT and CT images were acquired, the setup then acquired XLCT images using 
the EMCCD. The EMCCD was also coupled to a 100 micron slit aperture. Only 600 .5 second 
frames were acquired for each of the 15 positions required to take the image.  
6.5 X-ray CT Setup 
 
In order for the X-ray CT system to function, the Paxscan 1313, the X-ray CT source, and the 
sample stage must be arranged in a known geometrical configuration.  These geometrical 
parameters include the source to detector distance, Source to object distance, detector tilt,  
detector offset, sample stage offset, and central ray of cone beam location. All these parameters 
are necessary for successful and accurate X-ray CT reconstruction. 360 degree projections of a 
calibration phantom—each projection 1 degree apart—were incorporated into a preconditioned 
nonlinear conjugate gradient routine to determine the geometric prameters of the system. This 
calibration code was provided by a commecial company known as Xoran. The output of this data 
determined the parameters shown in Table 6.1 used in the experimental procedures for the mouse 
phantom as an example. The final CT reconstrution was performed via software called COBRA  
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purchased from the company known as EXXIM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PARAMETER DEFINITION VALUE 
SD Source to Detector Distance 434.3035 mm 
SO Source to Object Distance 124.000 mm 
TD Detector offset in x-direction -0.1157858 mm 
TC Distance between central ray and center-of-rotation .1035698 mm 
CS 
Central ray position from 
center of detector in Y-
direction. 
0.1845173 mm 
Β Detector Pivot -0.01085245 radians 
Table 6.1 The table depicts the geometric parameters used in the experiment procedure. 
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CHAPTER 7: RESULTS 
The double tube phantom from the XFCT/CT experiment produced the spectrum seen 
below in Figure 7.1.  The inner tube’s bromide 11.22 keV Kα1 peak and 12.5 keV Kβ1 peak is 
clearly visible in the spectrum. Additionally, the ytrrium 14.96 keV Kα1 peak and 16.96 keV 
Kβ1 peak. Surprisingly, zinc 9.57 and 8.64 keV peaks also appeared in the spectrum. When 
isolating those energies in Figure 7.2, we find that they come from the glass. 
Figure 7.2 shows the four energy isolated images of a single slice of the double tube. The 
gray scale in all 4 images is the CT image of the double tube. Figure 7.2A depicts the yttrium 
(green) within the double tube phantom. The yttrium was isolated by specifically selecting events 
registered on the CCD within the energy range of the yttrium peaks (as seen in Figure 7.1).  
Likewise, red in these images represents the bromide and the blue represents the zinc within the 
glass.  In these images, the primary X-ray source comes in from the bottom and the CCD is 
Y: 14.96 keV Kα1 
Y: 16.74 keV Kβ1 
Br: 12.5 keV Kβ1 
Br: 11.22 keV Kα1 
Zn: 8.64 keV Kα1 
Zn: 9.57 keV Kβ1  
Figure 7.1- The spectrum obtained from the double tube mouse phantom. The Zinc peaks are from 
the glass of the NMR tubes used.  
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placed on the left. The yttrium does not produce a full-ring due to self-attenuation on the primary 
beam and emitted fluorescence. The bromide data shows the same effect. This can be corrected 
using CT data to apply an attenuation correction. 
 Figure 7.3 shows the 3D rendered image obtained from X-ray fluorescence with X-ray CT. 
The mouse phantom was imaged in its entirety while the fluorescence was only imaged in a 
small region of interest. Figure 7.3 follows the same color scheme as Figure 7.2, with bromide 
fluorescence depicted in red, yttrium in green, zinc in blue, and the gray scale representing X-ray 
CT data. 
 
 
Figure 7.2: The gray scale portion of all these images are the ones obtained from X-ray CT. (A) 
The green represents counts found from yttrium fluorescence. (B) Zinc fluorescence from the glass 
was observed in blue. (C) The bromide fluorescence is represented in red. (D) A combination of all 
the energy isolated fluorescence using the earlier described color schemes. 
 
A 
 
B 
C D 
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 For the combined XFCT/XLCT/CT experiment, a spectrum as also obtained as seen in 
Figure 7.4. However, no lanthanum peaks were observed in the spectrum. Additionally, the 
16.74 peak had some level of contamination from 17.4 keV Mo primary peak. Thus, it was not 
used in the energy isolated fluorescence image seen in Figure 7.5B.  
Additionally, an XLCT image was also acquired using the previously described method. 
Luminescence from both the LaF3:Tb+3 and Y2O3:Eu+3. In Figure 7.5A, x-ray luminescence of 
yttrium (blue) and LaF3 (red) nanoparticles are depicted. 
 
  
Figure 7.3: The gray scale portion of all these images are the ones obtained from X-ray CT. The green 
represents counts found from yttrium fluorescence. Zinc fluorescence from the glass was observed in blue. (C) 
The bromide fluorescence is represented in red. A combination of all the energy isolated fluorescence using 
the earlier described color schemes. The image on the left shows the full mouse and double tube phantom 
while the image on the right is zoomed in on the tube. 
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Y: 14.96 keV Kα1 
Figure 7.4: Irradiation of the LaF3:Tb and Y2O3:Eu 
nanoparticles only resulted in the observation of yttrium 
peaks. 
Y: 16.74 keV Kβ1 
Figure 7.5: (A)  XLCT image of a slice of the mouse phantom with LaF3:Tb in red and 
Y2O3:Eu  in blue . (B) XFCT image of the sample. Yttrium is in green, and the LaF3 is 
not visible. 
A 
 
B 
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CHAPTER 8: DISCUSSION 
The experimental work carried out in this work suggests that using a combined 
XFCT/XLCT/CT setup to monitor PDT may be possible. In spectra, yttrium and bromide were 
clearly resolved. Also, unexpectedly, zinc fluorescence was found in the glass of the nuclear 
magnetic resonance tubes.  The images demonstrate the capability of using specified geometries 
in conjunction with aperture to create quantitative maps of a sample without reconstruction and 
its resulting decoding penalty. The experiments also depict the potential for producing 3D 
images by simply adding a vertical motor translation component to the same experiments. 
Regrettably, current acquisition times require a few days to obtain each of the specified slices. 
This currently prohibits the setup for any sort of in vivo use. Nevertheless, there are a few means 
to decrease acquisition times. These include attaching a multi-slit aperture onto the EMCCD and 
CCD, this would allow for a larger solid angle and thus would increase the overall sensitivity of 
the setup. Additionally, a more intense source would quickly reduce the necessary imaging time.  
The images also show the significant effect of the attenuation of both internal 
fluorescence X-rays and the primary radiation source as well. Figure 7.2 most clearly 
demonstrates this effect as only half the expected circle of bromide appeared in the final image 
despite the uniformity in concentration within the tube. However, the highest fluorescence count 
occurs at the entry points of the primary X-ray beam. Attenuation-based correction factors from 
X-ray CT still need to be applied to achieve more accurate quantitative information.  
Additionally, the Figure 7.4 and Figure 7.5 both show a lack of lanthanum in the fluorescence 
image and spectra. The k-edge of lanthanum is 38.9 keV, which is significantly higher than the 
17.4 keV excitation energy of the primary beam. Thus, no K-edge fluorescence is expected from 
lanthanum. The lack of L-energy fluorescence from lanthanum ranged from 4 keV to 6 keV. This 
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may not have been observed due to a low emission yield and/or due to the energy not being 
penetrative enough to escape the sample. 
However, Figure 7.5 does show a significant yield of light from both samples in the 
XLCT image. The larger the light yield, the more pronounced of a PDT effect would be expected 
in therapeutic settings. The ability to observe such a light yield is promising, but whether such a 
light yield would be observed in less ideal settings remains to be a question. 
Despite these limitations in the results, the data suggests that such an imaging system 
technique can work for in vitro settings and has plausibility in vivo environments. A camera in 
conjunction with a single slit aperture acquired data from a sample placed in a known geometric 
setup. Through this known geometry, an image was produced for each sample by mapping each 
sample position. This exemplifies the major benefit of volume selective counting: the ability to 
generate 2-D or 3-D images without image reconstruction and its decoding penalty. Given long 
enough acquisition times, a higher intensity laboratory X-ray source, and/or a multi-slit aperture, 
a spectrum could be produced for every motor position or ‘pixel’ of the image showing the full 
benefit of the volume selective counting technique.  
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CHAPTER 9: FUTURE WORK 
The focus of the future work in the current generation of the system will be on reducing 
the total acquisition time by increasing overall system, sensitivity, incorporating attenuation 
correction factors, determining minimum detectable concentrations of these nanoparticles, and 
exploring other nanoparticles. A proper method to correlate density and attenuate information to 
the X-ray fluorescence data has yet to be achieved, but other groups have made great strides and 
published works on correlating images from multi-modality systems [33], [34].  
Acquisition time of the CCD can be considered the sum of the readout time and the total 
exposure time to acquire significant X-ray fluorescence information. With the readout time being 
inherent in the equipment, only the exposire time can be reduced. The group plans to reduce 
exposure time through two main means. Firstly, the Xenocs source can be replaced with an even 
more intense source such as a medical linear accelerator, increasing the X-ray interaction 
probability, and, therefore, the number of fluorescence X-rays produced. Since this would be in 
the radiation therapy setting, dosage  is of less of a concern. 
Aside from increasing the primary beam flux, the number of photons that reach the CCD 
can be improved by adjusting the detector’s aperture. The effort presented in this work used a 
single-slit aperture, which attenuated a significant amount of photon information and 
underutilized the useable CCD surface area. By introducing additional slits that target the same 
sample segment as the single slit, exposure time can be drastically reduced as the sensitivity of 
the system increases in magnitudes of order. With such multi-slit aperture designs, the method 
for image formation would remain unaltered. Currently, designs for such aperture have already 
been created; however, and the authors are searching for a means to fabricate such intricately 
tapered apertures. Additionally, only one CCD or EMCCD detector was used in this experiment. 
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Greater sensitivity can be achieved by using a ring of detectors as seen in Figure 9.1. All these 
currently undergoing efforts would increase the sensitivity of the XFCT and XLCT system, 
potentially giving it the necessary foothold to entire in vivo research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1:A full ring of detector coupled with apertures to increase the 
sensitivity of the XFCT or XLCT setup. 
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CHAPTER 10: CONCLUSION 
 
In summary, this work explored the possibility of using a combinatorial system of X-ray 
fluorescence computed tomography (XFCT), x-ray luminescence tomography (XLCT), and 
conventional X-ray CT  (CT) imaging to provide real-time information on the therapeutic 
delivery of photodynamic therapy nanoparticles. Two phantom studies were conducted too 
demonstrate the plausibility of such a system. The first study produced a combined XFCT/CT 
3D image of a mouse phantom with a double tube containing NaBr and Y2O3 as well as a 
spectrum depicting the bromide and yttrium fluorescence peaks. The second experiment yielded 
a cross-sectional XLCT/XFCT/CT slice of two microcapillary tubes, containing LaF3:Tb3+ and 
Y2O3:Eu3+, attached to a 3D printed mouse.  
The results of these initial experiments show that conceptually using such a combinatorial 
system to monitor PDT could work, a few more questions need to be answers and some 
limitations need to be addressed. A minimum detectable concentration would need to be 
determined for these nanoparticles and system. Additionally, the current acquisition times are 
quite long to be performed for in vivo applications. Increasing sensitivity and reducing 
acquisition time can be achieved by using a ring of detectors attached to mult-slit apertures. 
Additionally, using nanoparticles with a higher K-edge could improve any penetration issues 
while using a strong flux source would also decrease acquisition time by producing greater 
luminescent and fluorescent yields. With these questions and limitations addressed, a 
combinatorial XFCT/XLCT/CT system could be seen monitoring the therapeutic delivery of 
PDT nanoparticles. 
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